{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:54:48Z","timestamp":1788843288465,"version":"build-2803163510"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00778-1","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:22:50Z","timestamp":1777098170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6814-8007","authenticated-orcid":false,"given":"Zuhal","family":"Naderi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-9580","authenticated-orcid":false,"given":"Teresa","family":"Sadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-7981","authenticated-orcid":false,"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-2966","authenticated-orcid":false,"given":"Ilaria S.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"5405","key":"778_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290\u20133.","journal-title":"Nature"},{"issue":"15","key":"778_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia\u2013advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451\u201364.","journal-title":"N Engl J Med"},{"key":"778_CR3","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022;14(1):215.","DOI":"10.3390\/pharmaceutics14010215"},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik E, Montazeri Aliabadi H. Do we know jack about JAK? a closer look at JAK\/STAT signaling pathway. Front Oncol. 2018;8:2018.","journal-title":"Front Oncol"},{"issue":"1","key":"778_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"P Singh","year":"2021","unstructured":"Singh P, Kumar V, Gupta SK, Kumari G, Verma M. Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review. Med Oncol. 2021;38(1):10.","journal-title":"Med Oncol"},{"issue":"47","key":"778_CR6","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21(47):7137\u201346.","journal-title":"Oncogene"},{"issue":"3","key":"778_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","volume":"110","author":"JS Chang","year":"2007","unstructured":"Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, et al. High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C\/EBPalpha-driven myeloid differentiation. Blood. 2007;110(3):994\u20131003.","journal-title":"Blood"},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.2147\/CMAR.S314343","volume":"13","author":"L Wang","year":"2021","unstructured":"Wang L, Li L, Chen R, Huang X, Ye X. Understanding and monitoring chronic myeloid leukemia blast crisis: how to better manage patients. Cancer Manag Res. 2021;13:4987\u20135000.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"778_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/asheducation-2018.1.177","volume":"2018","author":"CF Craddock","year":"2018","unstructured":"Craddock CF. We do still transplant CML. don\u2019t we? Hematol. 2018;2018(1):177\u201384.","journal-title":"don\u2019t we? Hematol"},{"issue":"10","key":"778_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"25","key":"778_CR11","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315\u201321.","journal-title":"Blood"},{"issue":"1","key":"778_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28\u201337.","journal-title":"Blood"},{"issue":"8","key":"778_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797\u2013813.","journal-title":"Leukemia"},{"issue":"11","key":"778_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11):2191\u2013212.","journal-title":"Am J Hematol"},{"issue":"14","key":"778_CR15","doi-asserted-by":"publisher","first-page":"e35953","DOI":"10.1002\/cncr.35953","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, et al. Management of chronic myeloid leukemia in 2025. Cancer. 2025;131(14):e35953.","journal-title":"Cancer"},{"issue":"24","key":"778_CR16","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"778_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood.2024026310","volume":"145","author":"TP Hughes","year":"2025","unstructured":"Hughes TP, Yong ASM, Ross DM. The evolution of treatment-free remission. Blood. 2025;145(9):921\u201330.","journal-title":"Blood"},{"issue":"2","key":"778_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440\u201353.","journal-title":"Leukemia"},{"issue":"20","key":"778_CR19","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients Trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"4","key":"778_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clml.2023.12.004","volume":"24","author":"\u00d6 S\u00f6nmez","year":"2024","unstructured":"S\u00f6nmez \u00d6, \u00d6zg\u00fcr Yurtta\u015f N, \u0130htiyaro\u011flu \u0130, \u00c7ak\u0131r HM, Atl\u0131 Z, Elverdi T, et al. Effect of tyrosine kinase inhibitor therapy on estimated glomerular filtration rate in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(4):232\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"778_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","volume":"75","author":"AM Pendergast","year":"1993","unstructured":"Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75(1):175\u201385.","journal-title":"Cell"},{"key":"778_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cytogfr.2025.05.001","volume":"83","author":"T Shammas","year":"2025","unstructured":"Shammas T, Peiris MN, Meyer AN, Donoghue DJ. BCR-ABL: The molecular mastermind behind chronic myeloid leukemia. Cytokine Growth Factor Rev. 2025;83:45\u201358.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"14","key":"778_CR23","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/sj.onc.1210841","volume":"27","author":"S Sahay","year":"2008","unstructured":"Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV, et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene. 2008;27(14):2064\u201371.","journal-title":"Oncogene"},{"issue":"1","key":"778_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr\u2013Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"778_CR25","doi-asserted-by":"publisher","first-page":"245101","DOI":"10.1063\/5.0133826","volume":"157","author":"K Krishnan","year":"2022","unstructured":"Krishnan K, Tian H, Tao P, Verkhivker GM. Probing conformational landscapes and mechanisms of allosteric communication in the functional states of the ABL kinase domain using multiscale simulations and network-based mutational profiling of allosteric residue potentials. J Chem Phys. 2022;157(24):245101.","journal-title":"J Chem Phys"},{"issue":"6513","key":"778_CR26","doi-asserted-by":"publisher","first-page":"eabc2754","DOI":"10.1126\/science.abc2754","volume":"370","author":"T Xie","year":"2020","unstructured":"Xie T, Saleh T, Rossi P, Kalodimos CG. Conformational states dynamically populated by a kinase determine its function. Science. 2020;370(6513):eabc2754.","journal-title":"Science"},{"issue":"5","key":"778_CR27","doi-asserted-by":"publisher","first-page":"e70005","DOI":"10.1002\/ardp.70005","volume":"358","author":"A Irgit","year":"2025","unstructured":"Irgit A, Kam\u0131s R, Sever B, Tuyun AF, Otsuka M, Fujita M, et al. Structure and dynamics of the ABL1 tyrosine kinase and its important role in chronic myeloid leukemia. Arch Pharm (Weinheim). 2025;358(5):e70005.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"6","key":"778_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859\u201371.","journal-title":"Cell"},{"issue":"12","key":"778_CR29","first-page":"7587","volume":"13","author":"JR McWhirter","year":"1993","unstructured":"McWhirter JR, Galasso DL, Wang JYJA, Coiled-coil. Oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13(12):7587\u201395.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"778_CR30","doi-asserted-by":"publisher","first-page":"e17020","DOI":"10.1371\/journal.pone.0017020","volume":"6","author":"M Preyer","year":"2011","unstructured":"Preyer M, Vigneri P, Wang JYJ. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS ONE. 2011;6(2):e17020.","journal-title":"PLoS ONE"},{"key":"778_CR31","doi-asserted-by":"crossref","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers (Basel). 2022;14(14):3300.","DOI":"10.3390\/cancers14143300"},{"issue":"5","key":"778_CR32","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology. Blood. 1999;94(5):1517\u201336.","journal-title":"Blood"},{"issue":"11","key":"778_CR33","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398\u2013406.","journal-title":"Leukemia"},{"issue":"7","key":"778_CR34","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825\u201333.","journal-title":"Leukemia"},{"issue":"5","key":"778_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312.","journal-title":"Cancer Cell"},{"issue":"7647","key":"778_CR36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"issue":"24","key":"778_CR37","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326.","journal-title":"N Engl J Med"},{"issue":"19","key":"778_CR38","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1182\/blood.2024024657","volume":"144","author":"DT Yeung","year":"2024","unstructured":"Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong ASM, et al. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993\u20132001.","journal-title":"Blood"},{"issue":"10","key":"778_CR39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim D-W, Kim DDH, Mayer J, Goh Y-T, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","journal-title":"N Engl J Med"},{"key":"778_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OTT.S289306","volume":"15","author":"S De Santis","year":"2022","unstructured":"De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, Soverini S. Overcoming resistance to kinase inhibitors: the paradigm of chronic myeloid leukemia. Onco Targets Ther. 2022;15:103\u201316.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"778_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276\u201383.","journal-title":"Blood"},{"issue":"10","key":"778_CR42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O\u2019Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20(10):1767\u201373.","journal-title":"Leukemia"},{"issue":"24","key":"778_CR43","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res. 2006;12(24):7374\u20139.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"778_CR44","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114(27):5426\u201335.","journal-title":"Blood"},{"issue":"1","key":"778_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/10428194.2018.1473573","volume":"60","author":"Y Erbilgin","year":"2019","unstructured":"Erbilgin Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, Elverdi T, Firtina S, et al. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leuk Lymphoma. 2019;60(1):200\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"778_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/jpgm.JPGM_781_20","volume":"68","author":"KB Bommannan","year":"2022","unstructured":"Bommannan KB, Naseem S, Binota J, Varma N, Malhotra P, Varma S. Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: a single center experience. J Postgrad Med. 2022;68(2):93\u20137.","journal-title":"J Postgrad Med"},{"issue":"2","key":"778_CR47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12288-022-01585-3","volume":"39","author":"H Gao","year":"2023","unstructured":"Gao H, Li L, Mu J, Tan J, Chen R. Efficacy of flumatinib in CML patients with F359V\/C mutation. Indian J Hematol Blood Transfus. 2023;39(2):344\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"25","key":"778_CR48","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim DW, M\u00fcller MC, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27(25):4204\u201310.","journal-title":"J Clin Oncol"},{"issue":"11","key":"778_CR49","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41375-024-02411-7","volume":"38","author":"AJ Innes","year":"2024","unstructured":"Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia. 2024;38(11):2443\u201355.","journal-title":"Leukemia"},{"key":"778_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021;13:19.","journal-title":"Cancers (Basel)"},{"issue":"17","key":"778_CR51","doi-asserted-by":"publisher","first-page":"13423","DOI":"10.18632\/oncotarget.24393","volume":"9","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget. 2018;9(17):13423\u201337.","journal-title":"Oncotarget"},{"issue":"12","key":"778_CR52","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/leu.2017.264","volume":"31","author":"W Qiang","year":"2017","unstructured":"Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31(12):2844\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"778_CR53","doi-asserted-by":"publisher","first-page":"e0192180","DOI":"10.1371\/journal.pone.0192180","volume":"13","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Dang P, Goyne JM, Hughes TP, White DL. ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE. 2018;13(1):e0192180.","journal-title":"PLoS ONE"},{"issue":"6","key":"778_CR54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood.2023022538","volume":"144","author":"A Leyte-Vidal","year":"2024","unstructured":"Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, et al. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024;144(6):639\u201345.","journal-title":"Blood"},{"issue":"7","key":"778_CR55","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14796694.2025.2464494","volume":"21","author":"A Costa","year":"2025","unstructured":"Costa A, Scalzulli E, Bisegna ML, Breccia M. Asciminib in the treatment of chronic myeloid leukemia in chronic phase. Future Oncol. 2025;21(7):815\u201331.","journal-title":"Future Oncol"},{"issue":"7","key":"778_CR56","doi-asserted-by":"publisher","first-page":"e1376","DOI":"10.1002\/hsr2.1376","volume":"6","author":"C Benjamin","year":"2023","unstructured":"Benjamin C, Murugan S, Hoosen S, Rapiti N. Chronic myeloid leukemia kinase domain mutations: a retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa. Health Sci Rep. 2023;6(7):e1376.","journal-title":"Health Sci Rep"},{"issue":"9","key":"778_CR57","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Investig. 2007;117(9):2562\u20139.","journal-title":"J Clin Investig"},{"issue":"9","key":"778_CR58","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024776","volume":"144","author":"LN Eadie","year":"2024","unstructured":"Eadie LN, Lagonik E, Page EC, Schutz CE, Heatley SL, McClure BJ, et al. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood. 2024;144(9):1022\u20136.","journal-title":"Blood"},{"issue":"9","key":"778_CR59","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","volume":"38","author":"IB Leske","year":"2024","unstructured":"Leske IB, Hantschel O. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib. Leukemia. 2024;38(9):2041\u20135.","journal-title":"Leukemia"},{"issue":"9","key":"778_CR60","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1038\/s41375-024-02353-0","volume":"38","author":"A Leyte-Vidal","year":"2024","unstructured":"Leyte-Vidal A, DeFilippis R, Outhwaite IR, Kwan I, Lee JY, Leavitt C, et al. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia. 2024;38(9):2046\u201350.","journal-title":"Leukemia"},{"key":"778_CR61","doi-asserted-by":"crossref","unstructured":"Jung BK, Wei\u00dfmann S, Schock C, Meggendorfer M, Haferlach T, Dicker F. Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study. Haematologica. 2026;111(2):764\u20137.","DOI":"10.3324\/haematol.2025.288776"},{"issue":"8","key":"778_CR62","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34(8):2074\u201386.","journal-title":"Leukemia"},{"issue":"4","key":"778_CR63","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","volume":"5","author":"RE Clark","year":"2021","unstructured":"Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5(4):1102\u20139.","journal-title":"Blood Adv"},{"issue":"9","key":"778_CR64","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948\u201361.","journal-title":"Blood"},{"issue":"9","key":"778_CR65","first-page":"2380","volume":"108","author":"N Shanmuganathan","year":"2023","unstructured":"Shanmuganathan N, Wadham C, Shahrin N, Feng J, Thomson D, Wang P, et al. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica. 2023;108(9):2380\u201395.","journal-title":"Haematologica"},{"issue":"23","key":"778_CR66","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood.2025030259","volume":"146","author":"N Shanmuganathan","year":"2025","unstructured":"Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, Maqsood M, Shahrin N, et al. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood. 2025;146(23):2821\u201332.","journal-title":"Blood"},{"issue":"4","key":"778_CR67","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","volume":"35","author":"S Adnan Awad","year":"2021","unstructured":"Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35(4):1087\u201399.","journal-title":"Leukemia"},{"key":"778_CR68","doi-asserted-by":"publisher","first-page":"S569","DOI":"10.1016\/S2152-2650(25)01942-1","volume":"25","author":"B Parsons","year":"2025","unstructured":"Parsons B, Harish R, Quinn K, Jones C, Jasper JR. CML-592: Characterization and efficacy of TERN-701 in pre-clinical models of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2025;25:S569.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"778_CR69","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2025-901","volume":"146","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Hughes T, Van Etten R, Andorsky D, Carre\u00f1o G, le Coutre P, et al. CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML. Blood. 2025;146(Supplement 1):901.","journal-title":"Blood"},{"issue":"Supplement 1","key":"778_CR70","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/blood-2025-3771","volume":"146","author":"A Hochhaus","year":"2025","unstructured":"Hochhaus A, Saussele S, Coiteux V, Kim D-W, Yang Y, Wang Q, et al. Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts. Blood. 2025;146(Supplement 1):3771.","journal-title":"Blood"},{"issue":"Supplement 1","key":"778_CR71","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2022-162700","volume":"140","author":"SD Gross","year":"2022","unstructured":"Gross SD, Eide CA, Burkard MR, Reister Schultz A, Aujay MA, Kintz S, et al. Elvn-001, a Next generation ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Blood. 2022;140(Supplement 1):3095\u20136.","journal-title":"Blood"},{"key":"778_CR72","doi-asserted-by":"publisher","first-page":"S568","DOI":"10.1016\/S2152-2650(25)01940-8","volume":"25","author":"M Mauro","year":"2025","unstructured":"Mauro M, Lang F, Kim D-W, Kim D, Kreil S, Coutre Pl, et al. CML-575: ENABLE: A Phase 1a\/1b Study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2025;25:S568.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"778_CR73","first-page":"469","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S, Olverembatinib. First Approval Drugs. 2022;82(4):469\u201375.","journal-title":"First Approval Drugs"},{"issue":"4","key":"778_CR74","doi-asserted-by":"publisher","first-page":"100766","DOI":"10.1016\/j.tranon.2020.100766","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Tang X, Luo J, Tu Z, Jiang K, et al. GZD824 as a FLT3, FGFR1 and PDGFR\u03b1 inhibitor against leukemia in vitro and in vivo. Translational Oncol. 2020;13(4):100766.","journal-title":"Translational Oncol"},{"issue":"3","key":"778_CR75","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","volume":"56","author":"X Ren","year":"2013","unstructured":"Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879\u201394.","journal-title":"J Med Chem"},{"issue":"1","key":"778_CR76","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","volume":"11","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, et al. Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial. JAMA Oncol. 2025;11(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"15","key":"778_CR77","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001;98(15):8554\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"778_CR78","first-page":"1885","volume":"38","author":"N Cruz-Rodriguez","year":"2024","unstructured":"Cruz-Rodriguez N, Tang H, Bateman B, Tang W, Deininger M. BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): the new frontier in the treatment of Ph+. leukemias? Leuk. 2024;38(9):1885\u201393.","journal-title":"leukemias? Leuk"},{"issue":"2","key":"778_CR79","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55(2):807\u201310.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"778_CR80","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","volume":"8","author":"K Shimokawa","year":"2017","unstructured":"Shimokawa K, Shibata N, Sameshima T, Miyamoto N, Ujikawa O, Nara H, et al. Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation. ACS Med Chem Lett. 2017;8(10):1042\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"18","key":"778_CR81","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","volume":"79","author":"GM Burslem","year":"2019","unstructured":"Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, et al. Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation. Cancer Res. 2019;79(18):4744\u201353.","journal-title":"Cancer Res"},{"issue":"20","key":"778_CR82","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","volume":"62","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Ren C, Liu L, Chen J, Shao Y, Sun N, et al. Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel-lindau (VHL) E3 ubiquitin ligase. J Med Chem. 2019;62(20):9281\u201398.","journal-title":"J Med Chem"},{"issue":"Supplement 1","key":"778_CR83","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1182\/blood-2024-211207","volume":"144","author":"N Cruz-Rodriguez","year":"2024","unstructured":"Cruz-Rodriguez N, Tang H, Rouhimoghadam M, Liao J, Bateman B, Bates B, et al. Targeting chronic myeloid leukemia with potent and specific BCR::ABL1 degraders. Blood. 2024;144(Supplement 1):4157.","journal-title":"Blood"},{"key":"778_CR84","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Tu\u00f1\u00f3n I, Hern\u00e1ndez-S\u00e1nchez M, Luis Ordo\u00f1ez J, Alonso-P\u00e9rez V, \u00c1lamo-Quijada M, Benito R et al. The CRISPR\/Cas9 system efficiently reverts the tumorigenic ability of BCR\/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget. 2017;8(16) :26027\u201326040.","DOI":"10.18632\/oncotarget.15215"},{"issue":"4","key":"778_CR85","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/crispr.2021.0009","volume":"4","author":"E Vuelta","year":"2021","unstructured":"Vuelta E, Ordo\u00f1ez JL, Alonso-P\u00e9rez V, M\u00e9ndez L, Hern\u00e1ndez-Carabias P, Salda\u00f1a R, et al. CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia. CRISPR J. 2021;4(4):519\u201335.","journal-title":"CRISPR J"},{"key":"778_CR86","doi-asserted-by":"crossref","unstructured":"Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P et al. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. Cell Rep Med. 2024;5(5):101521.","DOI":"10.1016\/j.xcrm.2024.101521"},{"issue":"4","key":"778_CR87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431\u2013. \u2013\u200943.e5.","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"778_CR88","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1182\/blood-2025-903","volume":"146","author":"T Ernst","year":"2025","unstructured":"Ernst T, le Coutre P, Crysandt M, Franke G-N, Illmer T, Burchert A, et al. Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial. Blood. 2025;146(Supplement 1):903.","journal-title":"Blood"},{"key":"778_CR89","volume-title":"CML14 (ASCENDANCE) \u2013 A study to assess efficacy of combination therapy with asciminib plus low dose dasatinib in newly diagnosed chronic phase Chronic Myeloid Leukaemia (CMl) with high risk genetics","author":"Australasian Leukaemia and Lymphoma Group","year":"2023","unstructured":"Australasian Leukaemia and Lymphoma Group. CML14 (ASCENDANCE) \u2013 A study to assess efficacy of combination therapy with asciminib plus low dose dasatinib in newly diagnosed chronic phase Chronic Myeloid Leukaemia (CMl) with high risk genetics. Volume ACTRN12623001338651. Australia: ANZCTR; 2023. Dec 19."},{"issue":"6","key":"778_CR90","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191(6):977\u201384.","journal-title":"J Exp Med"},{"issue":"3","key":"778_CR91","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329\u201341.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"778_CR92","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","volume":"12","author":"DJ Goff","year":"2013","unstructured":"Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12(3):316\u201328.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"778_CR93","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2011.285","volume":"26","author":"DH Mak","year":"2012","unstructured":"Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, et al. Activation of apoptosis signaling eliminates CD34\u2009+\u2009progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012;26(4):788\u201394.","journal-title":"Leukemia"},{"issue":"2","key":"778_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","volume":"140","author":"J Kuroda","year":"2008","unstructured":"Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol. 2008;140(2):181\u201390.","journal-title":"Br J Haematol"},{"issue":"3","key":"778_CR95","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339\u201347.","journal-title":"Am J Hematol"},{"key":"778_CR96","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","volume":"74","author":"K Sweet","year":"2018","unstructured":"Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, et al. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018;74:89\u201396.","journal-title":"Leuk Res"},{"key":"778_CR97","unstructured":"Sweet K, Othus M, Tantravahi S, Radich J, Thompson J, Mendler J, Boddy C, Kumar P, Atallah E, Perepu U, Pinilla-Ibarz J, Mosley A, Erba H. A phase 2, randomized trial of ruxolitinib in addition to BCR::ABL1 TKIS in CML patients with molecular evidence of disease (swog trial S1712) [abstract]. EHA Congress. 2024;13\u201316; Frankfurt, Germany. Abstract: S174."},{"issue":"Supplement 1","key":"778_CR98","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2025-904","volume":"146","author":"A Jain","year":"2025","unstructured":"Jain A, Iqbal U, Vale C, Hunter A, Wei W, Smith K, et al. Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast phase: a multicenter analysis by the h jean khoury cure CML consortium. Blood. 2025;146(Supplement 1):904.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00778-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:01:53Z","timestamp":1777104113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00778-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00778-1","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11"}}